ArticleNeuro-oncology2023

Phase II trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment.

Stephen J BagleyPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.